Highlight the significance of genetic evolution of H5N1 avian flu
http://www.cmj.org/Periodical/paperlist.asp?id=LW200694391205609707&linkintype=pubmed
LU Jia-hai, ZHANG Ding-mei, WANG Guo-ling
LU Jia-hai School of Public Health, Sun Yat-sen University, Guangzhou 510080, China; ZHANG Ding-mei School of Public Health, Sun Yat-sen University, Guangzhou 510080, China; WANG Guo-ling School of Public Health, Sun Yat-sen University, Guangzhou 510080, China
A growing concern has focused on the recent identification of influenza A H5N1 virus in Asia. Previously thought to infect only wild birds and poultry, H5N1 has now infected humans, cats, pigs, and other mammals in an ongoing outbreak, often with fatal results. According to a report from the World Health Organization (WHO), 217 human H5N1 cases have been confirmed and 123 of them have been fatal as of May 19, 2006.1 But many questions remain unanswered, for example how the H5N1 virus could cross species barriers and acquire the ability to infect humans; when and how the H5N1 virus will transmit effectively between humans and cause an influenza pandemic; and what are the determinants of its high virulence. This article summarizes research progress on the origin of H5N1 virus, factors determining pathogenicity, the contribution of genetic evolution to H5N1 species barrier traversal, human-to-human transmission, and problems in prevention and treatment of H5N1 avian influenza virus.
ORIGIN OF H5N1 VIRUS
The influenza viruses are grouped into three types, designated A, B, and C. Both B and C viruses are essentially human viruses. The influenza virus genome is segmented, and consists of eight fragments of RNA encoding approximately 8 proteins, including haemagglutinin (HA or H), neuraminidase (NA or N), nucleocapsid protein (NP), polymerase A protein (PA), polymerase B1 protein (PB1), polymerase B2 protein (PB2), matrix protein (M), and non-structural protein (NS). HA and NA are the surface proteins. There are 15 HA subtypes and 9 NA subtypes, designated H1-H15 and N1-N9 respectively. Influenza A is classified into serologically defined antigenic subtypes of the HA and NA major surface glycoproteins. An individual virus strain is designated by letters H and N, each followed by the number of the subtype. All of these HA and NA subtypes have been detected in waterfowl, which are the natural reservoir of all influenza A viruses. Occasionally, viruses are transmitted to other animals, including mammals and domestic poultry, resulting in transitory infections and outbreaks. Through adaptation by mutation or genetic reassortment, some of these viruses may establish species-specific permanent lineages of influenza A viruses that can lead to epidemics or epizootics in the new host.2
Three influenza pandemics occurred during the last century, the 1918 influenza, the 1957 pandemic influenza, and the 1968 pandemic influenza. The 1918 virus was an avian virus that adapted to humans through a series of point mutations.3 By contrast, the 1957 and 1968 pandemic influenza viruses were the products of reassortment, that is, three genes were derived from an avian influenza virus and the remaining five genes from the previously circulating human influenza viruses.4 Analysis of the sequences of all eight RNA segments of the influenza A/Goose/Guangdong/1/96 (H5N1) virus, isolated from a sick goose during an outbreak in Guangdong Province, China, in 1996, revealed that the HA gene of the virus was genetically similar to those of the H5N1 viruses isolated in Hong Kong in 1997.5 However, the replicative complex of H5N1/97 is highly homologous with that of the A/quail/Hong Kong/G1/97 (H9N2) virus6 and with that of the A/teal/Hong Kong/W312/97 (H6N1)7 virus. Therefore the H5N1, H6N1, and H9N2 influenza virus represent possible ancestors of the viruses that were transmitted to humans. These viruses continue to co-circulate in wild aquatic birds and poultry in China.8,9 Meanwhile the quail were found to be highly susceptible to A/Goose/Guangdong/1/96 (H5N1) virus, and the H6N1 and H9N2 virus continue to circulate in quails.10 Therefore quail were thought to be the likely original host of the H5N1/97 virus.
Early in 2005, the H5N1 virus was isolated from six apparently healthy migratory ducks at Poyang Lake, and 3.1% of the 1092 captured migratory ducks were found to have antibodies to H5N1. The H5N1 viruses were also isolated from 1.8% of all ducks of the markets in six provinces in southeastern China.11 Ducks experimently infected with H5N1 viruses isolated between 2003 and 2004 shed virus for 17 days, during which variant viruses with low pathogenicity were selected.12 Most of the infected ducks showed no signs of illness.13 These H5N1 viruses become less pathogenic to domestic ducks, but remain pathogenic to other domestic poultry and potentially to humans. Therefore the domestic ducks in southern China had a central role in the generation and maintenance of this virus. The wild birds may have contributed to the increasingly dissemination of the virus in Asia.14,15
FACTORS DETERMINING PATHOGENICITY
Broad tissue tropism and the ability to replicate systemically are important factors determining high pathogenicity in domestic chickens. Low pathogenic avian influenza viruses (LPAIV) replicate in limited tissues where host proteases, such as trypsin-like enzymes, are found. Highly pathogenic avian influenza viruses (HPAIV) possess inserted multiple basic amino acid residues in their HA, and the HA is cleaved into HA1 and HA2 by ubiquitous proteases such as furin. For this reason, HPAIV viruses can replicate in a broad range of tissues.16
Like other highly pathogenic influenza viruses, the 1918 virus has an HA protein that is cleaved into an active form in the absence of trypsin. However, unlike any other HA protein from highly pathogenic influenza viruses that have been characterized so far, the HA of 1918 virus does not have a multibasic cleavage site that can be cleaved by furin and furin-like proteases. Instead, its own NA protein is involved in cleavage of HA by a mechanism that is not yet understood. As a result, low pathogenic influenza viruses could potentially increase their virulence not only through mutations in their HA gene but also through mutations in their NA gene.17
H5N1 avian influenza virus strains where HA contains multiple basic amino acids at the cleavage site differ significantly in their ability to cause disease and death on animal models.8,18 Hence, other poorly characterized genotypic differences may contribute to the virulence, too.19 Further investigation revealed that in addition to the multiple basic amino acid cleavage site, pathogenicity is also determined by amino acids 97, 108, 126, 138, 212, and 217 of HA and an additional glycosylation site within the NA protein globular head.18 The NA protein facilitates the mobility of virions by removing sialic acid residues from the viral HA during entry and release from cells. Virus particles with low NA activity cannot be efficiently released from infected cells. Greater NA activity results in higher HA cleavage in multiple organs thereby enhancing virulence, specifically neurovirulence in mice.20 The NS gene also contributes to pathogenesis by disarming the interferon-based defense system of the host.21 Reverse genetic studies have found that an Asp→Glu substitution at residue 92 of the NS1 molecule of the human isolate A/HK/156/97 (H5N1) is associated with the induction of severe pathology in pigs.22 A sequence motif on the carboxyl terminus of NS1 protein may allow the H5N1 virus to bind to host cells and disrupt the activity of certain proteins in human cells, and therefore acts as a virulence factor. The carboxyl terminus of the NS1 proteins of the vast majority of avian H5N1 viruses contains a sequence motif Glu-Ser-Glu-Val (ESEV). Glu-Pro-Glu-Val (EPEV) was identified in the carboxyl terminus of the NS1 proteins of all virulent H5N1 viruses isolated from humans. By contrast, the carboxyl terminus of the NS1 proteins of low-virulence human influenza A usually contains a different sequence, Arg-Ser- Lys-Val (RSKV). The avian version of NS1 protein (ESEV, EPEV) seems to be more damaging to human cells than the NS1 (RSKV) that is usually found in human influenza strains. The NS1 protein in H5N1 virus and the high-mortality 1918 pandemic virus both have an avian motif, while the NS1 protein in low-mortality flu outbreaks in 1957 and 1968 contains a human motif that appears to be less capable of interacting with host proteins.23-25
The polymerase complex (including the PB1, PB2, and PA proteins) are also implicated in virulence. Some mutations can enhance the activity of polymerase and increase virulence in mice, and some of these mutations have been found in H5N1 HPAIV strains.26 A Glu→Lys substitution at residue 627 of the PB2 protein can increase the virus pathogenicity.22 Numerous studies indicate that pathogenicity depends on the functional integrity of each gene and a gene constellation that is optimal for infection. The pathogenicity of the same virus strain differs in different animals,16 indicating that the virulence is not only related to the etiological agent but also to the host condition. Therefore the virus-host interaction should be considered when carrying out research on pathogenicity.
H5N1 viruses isolated from 1997 to 2001 were not consistently transmitted efficiently among ducks and did not cause significant symptoms. However, in late 2002, outbreaks of highly pathogenic H5N1 influenza virus caused deaths among wild migratory birds and resident waterfowl including ducks in two Hong Kong parks.27 H5N1 influenza viruses isolated from apparently healthy domestic ducks in mainland of China have become progressively more pathogenic for mammals.22
CROSSING THE SPECIES BARRIER
Learning the precise molecular changes that allow the influenza virus to cross host species barriers is essential to develope an effective means of prevention. In aquatic birds, the natural hosts of influenza viruses, infection is usually asymptomatic and localized to the intestinal tract. H5N1 viruses have been actively reassorting and crossing interspecies-host barriers, moving from aquatic poultry to land-based poultry and, more recently, to wild terrestrial birds and humans.28 The molecular basis of the transmissibility of avian influenza viruses to mammals is not resolved, but undoubtedly involves multiple viral genes.
A deletion in the stalk of the NA molecule and increased glycosylation of the HA globular head are thought to be associated with adaptation to chickens.28,29 The HA gene is thought to be a determinant of host range because of its role in host cell recognition and attachment. The HA proteins of avian influenza virus species contain Gln226 and Gly228 residues, which form a narrow receptor binding pocket that favors binding of α2, 3 sialic acid. On the other hand, human species usually contain Leu226 and Ser228, which form a broad pocket that prefers α2, 6 sialic acid. These avian influenza viral strains gained human transmissibility, in part, by altering the binding preference of their HA proteins for human host cell receptors bearing sialic acid residues of the α2, 6 form.17
Cell surface receptors for both human and avian influenza viruses were identified in pig trachea, providing a milieu conducive to viral replication and genetic reassortment. Phylogenetic and epidemiologic analyses indicate that avian and human viruses have also been transmitted to pigs in nature and that they have reassorted in pigs and transmitted to humans.30 Virological and serological evidence of pig infection of H5N1 virus in Fujian Province has been obtained.22 A study on the pathogenicity of a HPAIV in different species of birds and mammals indicated that pig susceptibility to HPAIV virus is very low, so genetic reassortments of HPAIV virus in pigs is a possibility.16 Moreover, with continued replication, some avian-like swine viruses acquired the ability to recognize human virus receptors, raising the possibility that they may be directly transmitted to human beings.30
However, HA of the 1918 virus shows its avian-like Gln226 and Gly228 residues which create a narrow avian-like binding pocket that still allows for high-affinity binding of α2, 6 sialic acid. In fact, a Asp→Glu mutation at residue 190 in the HA of the 1918 virus switches its receptor binding preference to α2, 3 sialic acid. Consequently, just a single 190Asp→Glu mutation in the HA of the H5N1 strain could potentially switch its binding preference to α2, 6 sialic acid, and this is expected to be required for its evolution into a pandemic virus.17 Meanwhile, the Hong Kong-origin H5N1 viruses isolated from humans show receptor-binding properties that are typical of avian but not human viruses,29 yet they were still able to replicate and cause disease and death in humans. These observations indicate that receptor specificity is not the sole factor determining host range, and also that an intermediate host is not necessarily required for the first stage of transmission from birds to humans.31 Genes, such as polymerase, NA, and nucleoprotein are also known to contribute to the host range restriction of influenza A viruses.32 The enhanced activity of viral polymerase enables HPAIV to adapt to a mammalian host. The viral polymerase may be the driving component of early evolution of influenza A viruses in a new host that paves the way for new pandemic viruses. PB1 13Pro, 678Asn, PB2 627Lys and amino acids 362 to 581 sequences could also play an important role in virus replicating in mammalian cells.26,31 Recent evidence, however, suggests that extremely high doses of avian virus can directly infect humans. α2-3-linked sialic acids have now been found on ciliated cells of the human airway epithelium, which may help explain why these bird viruses have infected humans, especially when challenged in doses high enough to counter the inhibitory effects of respiratory mucins that contain α2-3-linked sialic acids.33
HUMAN-TO-HUMAN TRANSMISSION
Whether an H5N1 influenza pandemic will occur hinges on whether the viral strains acquire additional mutations that facilitate efficient human-to-human transmission. Studies have confirmed that H5N1 virus could infect cats, and that felines can transmit the virus to other cats and perhaps to humans.34 To date, in most of the human cases, the patients had well-documented exposure to sick or dying poultry, but there have been several episodes of possible person-to-person spread. Two health care workers who cared for patients in Hong Kong in 1997 were later found to have antibodies to H5, and one recalled having had a respiratory illness after exposure to one of the patients.35 In a family cluster of the disease in Thailand, the index patient became ill three to four days after her last exposure to dying household chickens. Avian influenza infection of the mother and aunt without exposure to poultry probably resulted from person-to-person transmission of this lethal avian influenza virus during unprotected nursing care to the critically sick index patient.36 In 2005, a 14-year-old Vietnamese girl was infected with H5N1 virus. She had no known direct contact with poultry, but had cared for her 21- year-old brother while he had a documented H5N1 virus infection. The NA gene and HA gene of the brother's virus were identical to that in the girl. The timing of infection in these two patients, together with the lack of known interaction of the girl with poultry, raised the possibility that the virus could have been transmitted from the brother to the sister.37
It is not known when, or even if, the H5N1 virus will evolve effective human-to-human transmission. The sequences of the polymerase proteins (PA, PB1, and PB2) of the 1918 virus and subsequent human viruses differ by only ten amino acids from the avian influenza virus consensus sequence (PB2 199Ala→Ser, PB2 475Leu→Met, PB2 567Asp→Asn, PB2 627Glu→Lys, PB1 375Asn/Thr→Ser, PA 55Asp→Asn, PA 100Val→Ala, PA 382Glu→Asp, PA 552Thr→Ser). Many or all of these residues must account for the ability of the polymerase complex to acquire human transmissibility by an avian influenza virus. The seven human forms out of the ten polymerase residues have already been observed individually in currently circulating H5N1 influenza viruses isolated from birds and humans. Under the selective pressure of a suboptimal growth rate in humans, the polymerase genes of an avian H5N1 virus that is currently circulating could potentially mutate at these ten residues and convert to the “human” forms. As a result, the virus may become better suited for efficient human-to-human transmission.3,4,17 Even if human-to-human transmission has not been conclusively identified at this point, we can anticipate that with more human cases, the risk of a more efficient human-to-human transmission of the virus remains a possibility.38
PROBLEMS IN PREVENTION AND TREATMENT
Inactivated influenza vaccines will provide the main method of prophylaxis against pandemic influenza. Influenza vaccines are currently prepared from virus that is grown in chicken embryos and inactivated by either formaldehyde or β-propiolactone.39 In a clinical trial, 451 healthy adult volunteers were vaccinated with two intramuscular doses of an inactivated H5N1 vaccine. Preliminary data indicate that the vaccine was well-tolerated and induced an antibody response predictive of protection.4 However, other clinical trials have shown that inactivated H5 vaccines induce minimal immune responses in humans.40 On the other hand, attempts to produce large quantities of vaccine from a highly pathogenic avian virus would be disastrous, since the virus would kill chicken embryos, vaccine yield would be substantially reduced, and vaccine quality would be compromised by contaminants from dead eggs. Recent technological developments such as reverse genetics have allowed us to manipulate the influenza virus genome so that we can construct safe, high-yielding vaccine strains. An H5 influenza virus vaccine derived from a 2003 human isolate has been developed using reverse genetic technology.40 All of the recombinant viruses grew well in eggs, were avirulent in chicks, and protected animals against a wild-type virus infection. However, the transition of reverse genetic technologies from the research laboratory to the manufacturing environment has presented new challenges. Production of a pandemic vaccine involves identification of a relevant strain, development of a strain that grows in eggs, incubation of eggs, harvesting allantoic fluids, purification and inactivation of the virus, potency testing, and clinical trials. Even under optimal conditions, and even if the virus was grown in a cell culture instead of eggs, this process requires 6 to 8 months. A pandemic influenza strain could spread around the world in half that time.41
A replication-incompetent, human adenoviral-vector- based, haemagglutinin subtype 5 influenza vaccine (HAd-H5HA) was developed, which induced both humoral and cell-mediated immune responses against avian H5N1 influenza viruses isolated from people.42 The Ad-vector-based delivery system may be an alternative way for the development of a pandemic influenza vaccine. Chickens were inoculated with a vaccine that expressed the full-length HA gene, then challenged with a dose of whole H5N1 virus. All immunized chickens survived developed strong HA-specific antibody responses, and showed no clinical signs of disease. All of the chickens immunized with a control vaccine died.23 Future vaccine strategies that may include more robust induction of responses from T cells such as cytotoxic T lymphocytes may provide better protection. Because manufacturing capacity is limited and cannot be augmented quickly, more research is needed to establish the smallest amount of antigen per dose that will confer sufficient protection. For example, the use of certain adjuvants can reduce the antigen requirement per vaccine by one-half to three-quarters.43
Currently, there are two groups of anti-influenza virus drugs: M2 blockers (amantadine, rimantadine) and neuramidinase inhibitors (oseltamivir, zanimivir). Rapid development of resistant influenza variants after amantadine treatment is one of the main drawbacks of M2 blockers. The molecular basis for the resistance to M2 blockers is the mutation at the 26, 27, 30, 31, and 34 amino acid residues of M2 protein.44 All of the H5N1 viruses isolated after 2003 contained the 31Ser→Asn mutation of M2 protein, hence the H5N1 virus is resistant to M2 blockers.45 Combination chemotherapy can reduce the emergence of drug-resistant influenza variants in vitro using an M2 blocker together with a neuramidinase inhibitor.46 Early therapy with NA inhibitors is probably beneficial, and even therapy initiated later in the illness may also limit ongoing viral replication. H5N1 virus infections may require higher doses of oseltamivir for longer periods than other types of influenza do.47 But oseltamivir- resistant H5N1 variants were isolated from two Vietnamese patients who died of the infection, in one case despite early initiation of treatment. The 292Arg→Lys, 294Asn→Ser, 274His→Tyr substitutions in the NA gene confers a high level of resistance to oseltamivir. The emergence of resistance to oseltamivir may have been due to the use of insufficient doses of the drug and resultant failure to eradicate the virus.47 But the worrisome prospect was raised that even with a therapeutic dose, oseltamivir resistance may develop during the course of illness and may affect clinical outcomes. However, antiviral treatment could still be expected to be beneficial when there is evidence of ongoing viral replication.47,48 A passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 can protect mice from H5N1 virus infection effectively, indicating an alternative method for H5N1 avian influenza therapy.49
CONCLUSION
Avian species constitute the origin of the human H5N1 avian influenza virus. The virus has not yet manifested effective human-to-human transmission, but the situation may change if the virus continues to mutate and assort during an epidemic. To respond to the H5N1 outbreak, it is necessary to detect the variation trends in the virus. To develop effective vaccine and drugs, it is important to clarify variation trends, the molecular epidemic character, and the pathogenic basis and the molecular mechanism allowing the virus to cross the species barrier.
In Netherlands/Germany in 2003, the highly pathogenic H7N7 influenza viruses that was lethal to poultry infected the eyes of more than 80 people and killed one person; H6 and H9 have spread from a wild aquatic bird reservoir to domestic poultry over the past 10 years. H9N2 viruses have also been associated with human infections in the mainland of China and Hong Kong. Avian influenza H10N7 seems to have crossed the species barrier from poultry to people for the first time. Hence, it is possible that the next influenza pandemic may not be due to H5N1.
REFERENCES
1. WHO (World Health Orgnization). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. (Accessed April 26, 2006 at:
http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_05_19 /en/index.html.)
2. Jong MD, Hien TT. Avian influenza A (H5N1). J Clin Virol 2006;35: 2-13.
3. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-893.
4. Fauci AS. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 2006; 124:.665-670.
5. Xu X, Subbarao, Cox NJ, Guo Y. Genetic characteri- zation of the pathogenic influenza A/Goose/Guangdong/ 1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999; 261:15-19.
6. Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses; were they the donors of the “internal” genes of H5N1 viruses in Hong Kong? Proc Natl Acad Sci U S A 1999; 96: 9363–9367.
7. Hoffmann E, Stech J, Leneva I, Krauss S, Scholtissek C, Chin PS, et al. Characterization of the influenza A gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1? J Virol 2000; 74:6309–6315.
8. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005; 79: 2191–2198.
9. Cauthen AN, Swayne DE, Schultz-Cherry S, Perdue ML, Suarez DL. Continued circulation in china of highly pathogenic avian influenza viruses encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and humans. J Virol 2000; 74: 6592–6599.
10. Webster RG, Guan Y, Peiris M, Walker D, Krauss S, Zhou NN, et al. Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J Virol 2002; 76: 118-126.
11. Normile D. Evidence points to migratory birds in H5N1 spread. Science 2006; 311:1225.
12. Hulse-Post DJ, Sturm-Ramirez KM, Humberd J, Seiler P, Govorkova EA, Krauss S, et al. Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci U S A 2005;102: 10682-10687.
13. Normile D. Ducks may magnify threat of avian flu virus. Science 2004; 306: 953.
14. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430: 209-213.
15. Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci 2006; 103: 2845-2850.
16. Isoda N, Sakoda Y, Kishida N, Bai GR, Matsuda K, Umemura T, et al. Pathogenicity of a highly pathogenic avian influenza virus, A/chicken/Yamaguchi/7/04 (H5N1) in different species of birds and mammals. Arch Virol 2006; 151: 1267-1279.
17. Russell CJ, Webster RG. The genesis of a pandemic influenza virus. Cell 2005;10:368-371.
18. Hulse DJ, Webster RG, Russell RJ, Perez DR. Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens. J Virol 2004; 78: 9954-9964.
19. Lewis DB. Avian flu to human influenza. Annu Rev Med 2006; 57:139-154.
20. Goto H, Wells K, Takada, Kawaoka Y. Plasminogen- binding activity of neuraminidase determines the pathogenicity of influenza A virus. J Virol 2001;75: 9297-9301.
21. Russell CJ, Webster RG. The genesis of a pandemic influenza virus. Cell 2005; 10:368-371.
22. Chen H, Deng G, Li Z, Tian G, Li Y, Jiao P, et al. The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A 2004; 101:10452–10457.
23. Hampton T. Avian flu researchers make strides. JAMA 2006; 295: 1107-1108.
24. Normile D. Genomic analysis hints at H5N1 pathogenicity. Science 2006;311: 457.
25. Krug RM. Clues to the virulence of H5N1 viruses in humans. Science 2006; 311:1562-1563.
26. Gabriel G, Dauber B, Wolff T, Planz O, Klenk HD, Stech J. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci U S A 2005; 102:18590-18595.
27. Sturm-Ramirez KM, Ellis T, Bousfield B, Bissett L, Dyrting K, Rehg JE, et al. Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. J Virol 2004; 78:4892-4901.
28. Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, Lipatov AS, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A 2004; 101: 8156-8161.
29. Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 1999; 73:1146-1155.
30. Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 1998; 72: 7367-7373.
31. Yao Y, Mingay LJ, Mccauley JW, Barclay WS. Sequences in influenza A virus PB2 protein that determine productive infection for an avian influenza virus in mouse and human cell lines. J Virol 2001; 75: 5410-5415.
32. Vines A, Wells K, Matrosovich M, Castrucci MR, Ito T, Kawaoka Y. The role of influenza A virus hemagglutinin residues 226 and 228 in receptor specificity and host range restriction. J Virol 1998; 72:7626-7631.
33. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 2006; 355:1143-1155.
34. Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R, et al. Avian H5N1 influenza in cats. Science 2004;306:241.
35. Buxton Bridges C, Katz JM, Seto WH, Chan PK, Tsang D, Ho W, et al. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis 2000; 181:344-348.
36. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1).N Engl J Med 2005;352:333-340.
37. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, et al. Isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.
38. Riedel S. Crossing the species barrier: the threat of an avian influenza pandemic. Proc (Bayl Univ Med Cent) 2006; 19:16-20.
39. Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004; 2: 842-847.
40. Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 2006; 24:3669- 3676.
41. Cinti S, Chenoweth C, Monto AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir? Infect Control Hosp Epidemiol 2005; 26: 852-854.
42. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, et al. Development of adenoviral-vector- based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367: 475-481.
43. Klaus Stohr. Avian influenza and pandemics-research needs and opportunities. N Engl J Med 2005; 352: 405-407.
44. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986; 18 Suppl B: 19-29.
45. Scholtissek C, Quack G, Klenk HD, Webster RG. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res 1998; 37: 83-95.
46. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006; 70: 121-131.
47. Moscona A. Oseltamivir resistance—disabling our influenza defenses. N Engl J Med 2005; 353:2633-2636.
48. de Jong MD, Thanh TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-2672.
49. Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab1) 2 in mice. Respir Res 2006; 7: 43.